Skip to content

Study · Systematic review · 2024

7 results

Comparative efficacy and safety of weekly tirzepatide versus weekly insulin in type 2 diabetes: A network meta-analysis of randomized clinical trials.

Ayesh H, Suhail S, Ayesh S, Niswender K

Diabetes, obesity & metabolism25 Jun 2024Cited by 6 (Europe PMC)

PMID38923379 (opens in a new tab)DOI10.1111/dom.15725 (opens in a new tab)PepBankPUB-38923379
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, a network meta-analysis found tirzepatide reduced HbA1c more than weekly insulin therapies.

    In plain wordsIn adults with type 2 diabetes, tirzepatide lowered HbA1c more than weekly insulin.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHbA1c reduction versus weekly insulin
    Study

    n: not reported in source

    Comparator
    Weekly insulin (icodec, basal insulin Fc)
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tirzepatide exhibited superior efficacy in reducing HbA1c levels compared with insulin therapies
    2 context sentences
    Summary · context
    To compare the efficacy and safety profiles of recent innovations in type 2 diabetes mellitus (T2DM), which include once-weekly formulations such as tirzepatide, a dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist, and once-weekly insulin options such as…
    Summary · context
    The primary outcome of interest was change in glycated haemoglobin (HbA1c), with change in fasting plasma glucose (FPG), body weight, incidence of hypoglycaemia, and treatment discontinuation as secondary outcomes.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, tirzepatide 15 mg gave the largest HbA1c reduction versus weekly insulin in a network meta-analysis.

    In plain wordsIn adults with type 2 diabetes, the 15 mg tirzepatide dose lowered HbA1c most compared with weekly insulin.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHbA1c reduction versus weekly insulin, 15 mg
    Study

    n: not reported in source

    Comparator
    Weekly insulin (icodec, basal insulin Fc)
    Analysis
    Primary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mgAs given in this study (human).

    Measurements

    Mean difference in HbA1c
    −1.27%
    tirzepatide 15 mg vs weekly insulin

    Source sentences

    Summary
    with the 15-mg dose showing the most significant reduction (mean difference [MD] -1.27, 95% confidence interval [CI] -1.49; -1.0).
    2 context sentences
    Summary · context
    To compare the efficacy and safety profiles of recent innovations in type 2 diabetes mellitus (T2DM), which include once-weekly formulations such as tirzepatide, a dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist, and once-weekly insulin options such as…
    Summary · context
    The primary outcome of interest was change in glycated haemoglobin (HbA1c), with change in fasting plasma glucose (FPG), body weight, incidence of hypoglycaemia, and treatment discontinuation as secondary outcomes.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, tirzepatide 15 mg ranked highest for fasting plasma glucose reduction in a network meta-analysis.

    In plain wordsIn adults with type 2 diabetes, tirzepatide 15 mg ranked first for lowering fasting blood sugar.

    Peptide
    Tirzepatide
    Outcome
    DecreaseFasting plasma glucose reduction versus weekly insulin, 15 mg
    Study

    n: not reported in source

    Comparator
    Weekly insulin (icodec, basal insulin Fc)
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    15 mgAs given in this study (human).

    Measurements

    Mean difference in fasting plasma glucose
    −0.7 unit not stated
    tirzepatide 15 mg

    Source sentences

    Summary
    In terms of FPG reduction, tirzepatide 15 mg ranked highest (MD -0.70, 95% CI -1.05; -0.34), followed by tirzepatide 10 mg and 5 mg.
    2 context sentences
    Summary · context
    To compare the efficacy and safety profiles of recent innovations in type 2 diabetes mellitus (T2DM), which include once-weekly formulations such as tirzepatide, a dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist, and once-weekly insulin options such as…
    Summary · context
    The primary outcome of interest was change in glycated haemoglobin (HbA1c), with change in fasting plasma glucose (FPG), body weight, incidence of hypoglycaemia, and treatment discontinuation as secondary outcomes.
  4. 04HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, tirzepatide 10 mg and 5 mg ranked after the 15 mg dose for fasting plasma glucose reduction in a network meta-analysis.

    In plain wordsIn adults with type 2 diabetes, tirzepatide 10 mg and 5 mg lowered fasting blood sugar less than 15 mg.

    Peptide
    Tirzepatide
    Outcome
    DecreaseFasting plasma glucose reduction ranking, 10 mg and 5 mg
    Study

    n: not reported in source

    Comparator
    Weekly insulin (icodec, basal insulin Fc)
    Analysis
    Secondary
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 mg and 5 mgAs given in this study (human).

    Source sentences

    Summary
    In terms of FPG reduction, tirzepatide 15 mg ranked highest (MD -0.70, 95% CI -1.05; -0.34), followed by tirzepatide 10 mg and 5 mg.
    2 context sentences
    Summary · context
    To compare the efficacy and safety profiles of recent innovations in type 2 diabetes mellitus (T2DM), which include once-weekly formulations such as tirzepatide, a dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist, and once-weekly insulin options such as…
    Summary · context
    The primary outcome of interest was change in glycated haemoglobin (HbA1c), with change in fasting plasma glucose (FPG), body weight, incidence of hypoglycaemia, and treatment discontinuation as secondary outcomes.
  5. 05HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, tirzepatide led to substantial weight loss, most pronounced at 15 mg, in a network meta-analysis.

    In plain wordsIn adults with type 2 diabetes, tirzepatide caused clear weight loss, largest at the 15 mg dose.

    Peptide
    Tirzepatide
    Outcome
    DecreaseWeight loss versus weekly insulin, 15 mg
    Study

    n: not reported in source

    Comparator
    Weekly insulin (icodec, basal insulin Fc)
    Analysis
    Secondary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    15 mgAs given in this study (human).

    Measurements

    Mean difference in body weight
    −12.13 unit not stated
    tirzepatide 15 mg

    Source sentences

    Summary
    Additionally, tirzepatide led to substantial weight loss, with the 15-mg dose exhibiting the most pronounced effect (MD -12.13, 95% CI -13.98; -10.27).
    2 context sentences
    Summary · context
    To compare the efficacy and safety profiles of recent innovations in type 2 diabetes mellitus (T2DM), which include once-weekly formulations such as tirzepatide, a dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist, and once-weekly insulin options such as…
    Summary · context
    The primary outcome of interest was change in glycated haemoglobin (HbA1c), with change in fasting plasma glucose (FPG), body weight, incidence of hypoglycaemia, and treatment discontinuation as secondary outcomes.
  6. 06HumanSystematic reviewSafety outcome

    In adults with type 2 diabetes, a network meta-analysis found higher treatment discontinuation with tirzepatide, particularly at higher doses.

    In plain wordsIn adults with type 2 diabetes, more people stopped tirzepatide than weekly insulin, especially at higher doses.

    Peptide
    Tirzepatide
    Outcome
    IncreaseTreatment discontinuation versus weekly insulin
    Study

    n: not reported in source

    Comparator
    Weekly insulin (icodec, basal insulin Fc)
    Analysis
    Secondary
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, a higher incidence of adverse events (AEs) and treatment discontinuation were associated with tirzepatide, particularly at higher doses.
    2 context sentences
    Summary · context
    To compare the efficacy and safety profiles of recent innovations in type 2 diabetes mellitus (T2DM), which include once-weekly formulations such as tirzepatide, a dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist, and once-weekly insulin options such as…
    Summary · context
    The primary outcome of interest was change in glycated haemoglobin (HbA1c), with change in fasting plasma glucose (FPG), body weight, incidence of hypoglycaemia, and treatment discontinuation as secondary outcomes.
  7. 07HumanSystematic reviewSafety outcome

    In adults with type 2 diabetes, a network meta-analysis found a higher incidence of adverse events with tirzepatide, particularly at higher doses.

    In plain wordsIn adults with type 2 diabetes, side effects were more common with tirzepatide than with weekly insulin, especially at higher doses.

    Peptide
    Tirzepatide
    Outcome
    IncreaseAdverse events incidence versus weekly insulin
    Study

    n: not reported in source

    Comparator
    Weekly insulin (icodec, basal insulin Fc)
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, a higher incidence of adverse events (AEs) and treatment discontinuation were associated with tirzepatide, particularly at higher doses.
    2 context sentences
    Summary · context
    To compare the efficacy and safety profiles of recent innovations in type 2 diabetes mellitus (T2DM), which include once-weekly formulations such as tirzepatide, a dual glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptor agonist, and once-weekly insulin options such as…
    Summary · context
    The primary outcome of interest was change in glycated haemoglobin (HbA1c), with change in fasting plasma glucose (FPG), body weight, incidence of hypoglycaemia, and treatment discontinuation as secondary outcomes.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.